Lorundrostat

Lorundrostat

Clinical data
Other names	MLS 101
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-(4-Acetamidocyclohexyl)-2-[4-[5-(4-methylphenyl)-1,2,4-triazin-3-yl]piperazin-1-yl]acetamide
CAS Number	1820940-17-7
PubChem CID	126567187
ChemSpider	123963150
UNII	KA8W5LDS6Z
KEGG	D12773
ChEMBL	ChEMBL5095105
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H33N7O2
Molar mass	451.575 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC=C(C=C1)C2=CN=NC(=N2)N3CCN(CC3)CC(=O)NC4CCC(CC4)NC(=O)C
InChI InChI=1S/C24H33N7O2/c1-17-3-5-19(6-4-17)22-15-25-29-24(28-22)31-13-11-30(12-14-31)16-23(33)27-21-9-7-20(8-10-21)26-18(2)32/h3-6,15,20-21H,7-14,16H2,1-2H3,(H,26,32)(H,27,33) Key:YHGVDZULVMINCJ-UHFFFAOYSA-N

Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants.